OBIO Orchestra BioMed Holdings Inc
Price (delayed)
$2.85
Market cap
$109.19M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.66
Enterprise value
$103.46M
Highlights
The equity has plunged by 52% YoY and by 29% from the previous quarter
Orchestra BioMed Holdings's quick ratio has decreased by 47% YoY
Key stats
What are the main financial stats of OBIO
Market
Valuations
Earnings
Shares outstanding
38.31M
Market cap
$109.19M
Enterprise value
$103.46M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.29
Price to sales (P/S)
39.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.22
Revenue
$2.64M
Gross profit
$2.43M
Operating income
-$64.3M
Net income
-$61.02M
EBIT
-$61.02M
EBITDA
-$60.06M
Free cash flow
-$50.85M
Per share
Balance sheet
Liquidity
EPS
-$1.66
EPS diluted
-$1.66
Free cash flow per share
-$1.38
Book value per share
$0.87
Revenue per share
$0.07
TBVPS
$2.07
Total assets
$76.17M
Total liabilities
$43.22M
Debt
$16.53M
Equity
$32.96M
Working capital
$52.96M
Debt to equity
0.5
Current ratio
4.27
Quick ratio
4.13
Net debt/EBITDA
0.1
Margins
Efficiency
Dividend
EBITDA margin
-2,276.8%
Gross margin
92.3%
Net margin
-2,313.3%
Operating margin
-2,437.5%
Return on assets
-79.6%
Return on equity
-135.2%
Return on invested capital
-138.9%
Return on capital employed
-101.8%
Return on sales
-2,313.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OBIO stock price
How has the Orchestra BioMed Holdings stock price performed over time
Intraday
-0.35%
1 week
-0.35%
1 month
-36.81%
1 year
-36.95%
YTD
-28.75%
QTD
-33.41%
Financial performance
How have Orchestra BioMed Holdings's revenue and profit performed over time
Revenue
$2.64M
Gross profit
$2.43M
Operating income
-$64.3M
Net income
-$61.02M
Gross margin
92.3%
Net margin
-2,313.3%
OBIO's operating margin is down by 31% YoY and by 7% QoQ
Orchestra BioMed Holdings's net margin has decreased by 30% YoY and by 6% from the previous quarter
The operating income has declined by 25% year-on-year and by 7% since the previous quarter
OBIO's net income is down by 24% YoY and by 6% QoQ
Growth
What is Orchestra BioMed Holdings's growth rate over time
Valuation
What is Orchestra BioMed Holdings stock price valuation
P/E
N/A
P/B
3.29
P/S
39.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.22
Orchestra BioMed Holdings's EPS has decreased by 12% YoY and by 3.1% from the previous quarter
The equity has plunged by 52% YoY and by 29% from the previous quarter
The price to book (P/B) is 30% lower than the last 4 quarters average of 4.7
OBIO's price to sales (P/S) is 55% less than its last 4 quarters average of 88.6
Orchestra BioMed Holdings's revenue has decreased by 4.4% YoY
Efficiency
How efficient is Orchestra BioMed Holdings business performance
Orchestra BioMed Holdings's return on invested capital has shrunk by 161% YoY and by 6% QoQ
OBIO's ROE has dropped by 132% year-on-year and by 26% since the previous quarter
The company's return on assets has shrunk by 92% YoY and by 12% QoQ
Orchestra BioMed Holdings's ROS has decreased by 30% YoY and by 6% from the previous quarter
Dividends
What is OBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OBIO.
Financial health
How did Orchestra BioMed Holdings financials performed over time
The company's total assets is 76% higher than its total liabilities
OBIO's total liabilities has soared by 59% YoY and by 49% QoQ
Orchestra BioMed Holdings's quick ratio has decreased by 47% YoY
Orchestra BioMed Holdings's debt is 50% less than its equity
The equity has plunged by 52% YoY and by 29% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.